gemcitabine,cisplatin,carboplatin,enfortumab,pembrolizumab
astellas,seagen,merck
['bladder', ' uc,(-ucsd),(-ucsf),', 'cisplatin', 'enfortumab', 'pembro', ' vedo', 'ev-103']
#asco23 excellent talk by dr. on long term update on ev-103 study of enfortumab vedotin + pembrolizumab in 1st line cisplatin-ineligible metastatic uc #bladdercancer setting median os~26 mos, orr: 73%. no new safety signals. 
Medical Oncologist. Editor-in-chief: @ASCO Daily News; Presidential Endowed Chair, @HuntsmanCancer (NCI-CCC) @UUtah, FCOI https://t.co/ywWAdZmBWt